Results 201 to 210 of about 20,735 (212)

Two-dose ChAdOx1 nCoV-19 vaccine protection against COVID-19 hospital admissions and deaths over time: a retrospective, population-based cohort study in Scotland and Brazil

Lancet, The, 2022
Thiago Cerqueira-Silva, Eleftheria Vasileiou, Chris Robertson   +2 more
exaly  

ChAdOx1-HBV Vaccine Safety Study

Case Medical Research, 2020
openaire   +1 more source

Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial

Lancet, The, 2021
Alasdair P S Munro, Victoria R Cornelius, Parvinder Aley   +2 more
exaly  

Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine

New England Journal of Medicine, 2021
Ian Hirsch, Lawrence Corey, Susan J Little   +2 more
exaly  

Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6–17 years: a preliminary report of COV006, a phase 2 single-blind, randomised, controlled trial

Lancet, The, 2022
Grace Li, Federica Cappuccini, Parvinder Aley   +2 more
exaly  

Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial

Lancet, The, 2020
Maheshi N Ramasamy, Angela M Minassian, Pedro M Folegatti   +2 more
exaly  

SARS-CoV-2 delta variant neutralisation after heterologous ChAdOx1-S/BNT162b2 vaccination

Lancet, The, 2021
Metodi V Stankov, Inga Nehlmeier, Markus Hoffmann   +2 more
exaly  

Bipolar Mania Following ChAdOx1-S/nCoV-19 Vaccination

The Primary Care Companion For CNS Disorders, 2021
openaire   +2 more sources

Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant

New England Journal of Medicine, 2021
Shabir A Madhi, Clare L Cutland, Merryn Voysey   +2 more
exaly  

SAEs after BNT162b2, CoronaVac and ChAdOx1 vaccination

Reactions Weekly, 2022
openaire   +1 more source